ObsEva Slashes 70% Of Staff To Survive
Restructuring Takes Effect At Swiss Biotech
Having surrendered the rights to linzagolix, its GnRH antagonist for bleeding associated with uterine fibroids that the FDA blocked, ObsEva is showing the door to most of its staff in a bid to cut costs and keep in business.
